Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Quantitative analysis of different respiratory specimens on two automated test systems for detection of SARS-CoV-2 RNA

Nadine Lübke a,*, Katharina Repges a, Christopher Menne a, Andreas Walker a, Björn-Erik O. Jensen b, Noemi F. Freise b, Smaranda Gliga c, Simon B. Eickhoff c, d, Hans Martin Bosse e, Ortwin Adams a, Jörg Timm a

a Institute of Virology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
b Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital, Medical Faculty, Heinrich-Heine-University Düsseldorf, Germany
c Institute of Systems Neuroscience, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
d Institute of Neuroscience and Medicine, Brain & Behaviour (INM-7), Research Centre Jülich, Jülich, Germany
e Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children’s Hospital, University Hospital, Medical Faculty, Heinrich-Heine-University Düsseldorf, Germany

ABSTRACT

Molecular testing of SARS-CoV-2 RNA is essential during the pandemic. Here, we compared the results of different respiratory specimens including anterior nasal swabs, pharyngeal swabs, saliva swabs, and gargle lavage samples to nasopharyngeal swabs on two automated SARS-CoV-2 test systems. Samples were collected and tested simultaneously from a total of 36 hospitalized symptomatic COVID-19 patients. Detection and quantification of SARS-CoV-2 was performed on cobas® 6800 (Roche) and NeuMoDx™ (Qiagen) systems. Both assays showed reliable detection and quantification of SARS-CoV-2 RNA, with nasopharyngeal swabs showing the highest sensitivity. SARS-CoV-2 RNA concentrations in other respiratory specimens were lower (mean 2.5 log10 copies/ml) or even undetectable in up to 20%. These data clearly indicate that not all respiratory materials are equally suitable for the management of hospitalized patients, especially, in the late phase of COVID-19, when the viral phase subsides and inflammation becomes the predominant factor, making detection of even lower viral loads increasingly important.

© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

The global spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the required expansion of testing capacities was an enormous global effort. Early identification and sequencing enabled very rapid development of SARS-CoV-2 detection protocols [1]. However, most in-house protocols are labor-intensive, and the massive use of quantitative RT-PCR (qPCR) protocols resulted in shortage of extraction and qPCR reagents [2–4]. In parallel, commercial assays were developed including fully automated SARS-CoV-2 systems for high-throughput testing [5]. In spring 2020, Roche’s cobas® SARS-CoV-2 test received an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for the qualitative detection of SARS-CoV-2 RNA in nasopharyngeal and oropharyngeal swabs on Roche’s fully automated cobas® 6800 and cobas® 8800 systems [6]. During 2020, additional commercial SARS-CoV-2 RNA assays received EUA status for in vitro diagnostic devices (IVD), including the NeuMoDx™ SARS-CoV-2 test (Qiagen), automated on the NeuMoDx random-access platform [7,8].

To control the spread of SARS-CoV-2 infection, massive screening measures were initiated to identify both asymptomatic SARS-CoV-2 infections and infections before the onset of symptoms [9–11]. Since SARS-CoV-2 infections in the younger population and in children are often asymptomatic, and vaccinations are not yet recommended in all age groups, schools and child care facilities are of particular interest [12,13]. In this age group, the recommended nasopharyngeal and throat swabs are difficult to perform and must be performed by trained medical personnel. Therefore, several screening studies were initiated using respiratory materials such as saliva swabs, anterior nasal swabs or gargle lavage, which can be obtained in a minimally invasive procedure [9–11,14–16]. Notably, the performance of high-throughput test systems with such alternative specimens from the upper respiratory tract is still unclear. In hospitalized patients, monitoring of SARS-CoV-2 RNA concentrations is important for the management of antiviral therapy as well as decision making in hospital hygiene. Reliable quantification of SARS-CoV-2 RNA is therefore particularly relevant in the hospital setting.
The objective of this study was therefore to directly compare detection rates and quantitative results of the recommended nasopharyngeal and throat swabs to different minimally invasive respiratory specimens on the fully automated SARS-CoV-2 test systems cobas® 6800 and NeuMoDxTM.

2. Material and methods

2.1. Study cohort

All study participants were hospitalized for symptomatic SARS-CoV-2 infection, but none required intensive care. A total of 36 patients with confirmed SARS-CoV-2 infection were recruited for the study. To participate, patients had to have a confirmed SARS-CoV-2 infection on a nasopharyngeal swab and a written informed consent from the patient or guardian to participate in the study. Approval from the local ethics committee was obtained (Study-ID.: 2021-1291).

The study participants were recruited in autumn 2020. Since no vaccines were available at that time and the spread of new clinically relevant SARS-CoV-2 variants was not documented until February 2021, we assume unvaccinated patients with SARS-CoV-2 wild-type (B.1 variant) infections.

2.2. Respiratory specimens

For the comparative analysis, different respiratory materials were obtained simultaneously from the study participants. While the recommended nasopharyngeal swab (NPS) and throat swabs were performed by medical personal, the anterior nasal swabs, the saliva swabs, and the gargle lavage using 10 ml NaCl2 were self-collected by the study participants. Detection of SARS-CoV-2 in the NPS was mandatory for comparative analysis.

2.3. Sample preparation

All respiratory materials obtained were processed on the same working day. To minimize the influence of inhibitory interfering factors in respiratory materials on PCR, samples were diluted and centrifuged prior to PCR (cobas® 1:2.5; NeuMoDx™ 1:4.3). The dilutions were performed with cell culture medium (DMEM). The samples were tested according to the manufacturer’s instructions.

2.4. RT-PCR platforms

Detection of SARS-CoV-2 RNA was performed using two different commercial RT-qPCR assays, automated on the cobas® 6800 (cobas, Roche) and on the NeuMoDx™ (NeuMoDx, Qiagen). Both are dual target assays and detect 2 different target genes of SARS-CoV-2, 1 structural and 1 nonstructural protein (cobas®: ORF1, E gene; NeuMoDx: NSP2, N gene).

2.5. Quantification of SARS-CoV-2 RNA

In order to compare different test systems directly with each other, it is necessary to use reference material, so-called standards. To compare the cobas 6800 and the NeuMoDx SARS-CoV-2 assays in terms of their sensitivity, the cycle threshold (Ct) values must be correlated with quantitative reference samples. For the direct comparison between the cobas 6800 and NMDx the quantitative SARS-CoV-2 reference samples provided by INSTAND e.V. (Society for the Promotion of Quality Assurance in Medical Laboratories) were used to compare Ct-values [17]. The quantitative reference samples are SARS-CoV-2 positive cell culture supernatants with 10⁷ copies/ml and 10⁹ copies/ml, respectively. To determine the SARS-CoV-2 RNA concentration for a given Ct-value, the quantitative reference samples were used in serial dilutions and a standard curve was established. The calculated SARS-CoV-2 RNA concentrations for 2 target genes are given as mean values.

2.6. Statistics

Statistical analysis was performed using GraphPad online calculator (https://www.graphpad.com/quickcalc/kappa1/) and GraphPad Prism 9.01. The level of agreement between c6800 and NMDx results was calculated using Cohen’s kappa statistics. Ct-values and SARS-CoV-2 RNA concentrations were tested for normal distribution with the Shapiro-Wilk method. Multiple Wilcoxon matched-pairs signed rank tests were used to compare individual specimen types between the NMDx and the c6800 assays and the adjusted P-value was calculated with the Holm-Sidak method. Differences between specimen types within 1 assay were compared by Friedman test followed by Dunns multiple comparisons test. A P-value <0.05 was considered statistically significant.

3. Results

In total, 180 respiratory samples of 36 patients infected with SARS-CoV-2 (f = 13 (36.1%), m = 23 (63.9%)) with a median age of 56.5 years (19–90 years) were analyzed.

The SARS-CoV-2 analyses of the various respiratory materials showed different detection rates compared to the NPS as the gold standard (Table 1). While both, the nasal and the throat swab showed a high detection rate of 91.7%, detection rates were lower with the saliva swab (c6800: 83.3% and NMDx: 80.6%) and the gargle lavage samples (80.6% and 72.2%). Notably, in these latter 2 specimens the detection rate of SARS-CoV-2 RNA was reproducibly lower with the NMDx assay than with the c6800 assay (Table 1).

When comparing the concordance of SARS-CoV-2 RNA detection between the 2 assays, an agreement of 100% was observed with the anterior nasal swab and throat swab (Table 2). There was also agreement between the 2 systems regarding the negative result in 3 identical swabs from the anterior nasal and pharyngeal cavities. In contrast, the saliva swab and the gargle lavage only achieved overall agreements of 86.1% and 88.9% (k=0.531 and k=0.709), respectively, with the gargle lavage showing the highest false negative rate of 19.4% in both SARS-CoV-2 assays. Overall, the c6800 assay performed slightly better with saliva swabs and gargle lavages compared to the NMDx assay, where 3 and 4 samples (8.3% and 11.1%, respectively) were tested positive on the c6800 and negative in the NMDx assay. In turn, 2 saliva swabs (5.6%) were tested positive in the NMDx assay despite being tested negative in the c6800 assay. Notably, discordant results were associated with high Ct-values (Ct >32; Supplemental Table 1).

A detailed comparison of the Ct-values determined in both SARS-CoV-2 assays showed minimal differences between individual target genes, but clear differences related to the respiratory material (Fig. 1, Supplemental Table 1). Regardless of the target gene, the NPS samples showed the lowest median Ct-values (Ct: 24.76) followed by the throat swab and nasal swab (Ct: 27.56 and Ct: 29.39, respectively). Both saliva swabs and gargle lavage samples provided median Ct-values >32 (Ct: 32.89 and Ct: 33.04, respectively). Overall, the

| Table 1 | Agreement of SARS-CoV-2 detection rate of different respiratory specimens compared to the nasopharyngeal swab (NPS). |
|---|---|---|---|---|
| Concordance | Nasal swab % | Throat swab % | Saliva swab % | Gargle lavage % |
| NPS | (n) | (n) | (n) | (n) |
| c6800 | 91.7 (33) | 91.7 (33) | 83.3 (30) | 80.6 (29) |
| NMDx | 91.7 (33) | 91.7 (33) | 80.6 (29) | 72.2 (25) |
nonstructural proteins Nsp2 and ORF1 yielded lower Ct-values than the structural proteins, independent of the material used (Fig. 1). These data clearly demonstrate the limitations of a quantitative statement based on individual Ct-values when the assay is not calibrated to a quantitative standard. Accordingly, for direct comparison of the 2 SARS-CoV-2 assays on the different platforms the SARS-CoV-2 RNA was quantified using a standardized reference material.

Overall, similar SARS-CoV-2 RNA concentrations were detected with both analyzed automated SARS-CoV-2 assays ranging from 3.932 to 6.379 log10 cop/ml with the c6800 and from 3.527 to 6.415 log10 cop/ml with the NMDx assay, depending on the respiratory material (Fig. 2, Table 3).

Looking at the differences in respiratory specimen, according to the determined Ct-values, the NPS provided the highest SARS-CoV-2 RNA concentrations with a median of 6.379 log10 copies/ml (IQR: 5.144-7.922) with the c6800 and from 6.415 log10 copies/ml with the NMDx assay, depending on the respiratory material (Fig. 2 and Table 3). Both the saliva swabs and the gargle lavages samples yielded in average 2.5 log10 lower SARS-CoV-2 RNA concentrations compared to the NPS (c6800: 3.932 log10 cop/ml and 4.114 log10 cop/ml, and NMDx: 3.792 log10 cop/ml and 3.527 log10 cop/ml, P < 0.0001, respectively). Of note, the nasal and throat swabs had similar median SARS-CoV-2 RNA concentrations regardless of the assay (c6800: 5.061 log10 cop/ml and 5.585 log10 cop/ml, and NMDx: 4.802 log10 cop/ml and 5.476 cop/ml, P > 0.9999, respectively), but concentrations were on average 0.8 (throat swab) and 1.4 (anterior nasal swab) log10 levels lower compared to the NPS.

4. Discussion

During the COVID-19 pandemic, it was necessary to develop reliable assays for the detection of SARS-CoV-2 infections in a very short period of time. This has resulted in many commercial SARS-CoV-2 tests coming to market shortly after the onset of the pandemic [7,18]. In order to make more efficient use of laboratory capacity, tests for automated platforms have been developed in addition to standard real-time PCR assays [19].

In this study, the SARS-CoV-2 assay from Roche for the c6800 and from Qiagen for the NMDx platform were compared. For this purpose, not only the generally recommended specimens such as nasopharyngeal swabs or throat swabs were used, but also less invasive and easier to obtain respiratory specimens such as anterior nasal swabs, saliva swabs, and gargle lavages, which have been used primarily in children but also in many cases for SARS-CoV-2 screening [11,20–23].

While the c6800 system is well established in diagnostic workflows for many years, the NMDx system is available since the end of 2018 and therefore the most recent platform in the field of molecular virus diagnostics. Nevertheless, open channel reagents were offered for this platform prior to the availability of commercial kits, enabling

---

**Table 2**

Agreement of SARS-CoV-2 detection between c6800 and NMDx SARS-CoV-2 assays.

| c6800/NMDx | NPS % (n) | Nasal swab % (n) | Throat swab % (n) | Saliva swab % (n) | Gargle lavage % (n) |
|------------|-----------|------------------|------------------|------------------|-------------------|
| Overall agreement (kappa value, 95% CI,) | 100 (36); (k=1, 1.000-1.000) | 100 (36); (k=1, 1.000-1.000) | 100 (36); (k=1, 1.000-1.000) | 86.1 (31); (k=0.531, 0.171 to 0.891) | 88.9 (32); (k=0.709, 0.451 to 0.966) |

### Agreement and Disagreement

| c6800/NMDx | NPS % (n) | Nasal swab % (n) | Throat swab % (n) | Saliva swab % (n) | Gargle lavage % (n) |
|------------|-----------|------------------|------------------|------------------|-------------------|
| +/+        | 100 (36)  | 91.7 (33)        | 91.7 (33)        | 75 (27)          | 69.4 (25)         |
| -/-        | 0         | 8.3 (3)          | 8.3 (3)          | 11.1 (4)         | 19.4 (7)          |
| Overall disagreement | 0 | 0 | 0 | 8.3 (3) | 11.1 (4) |
| -/+        | 0         | 0                | 0                | 0                | 0                 |
| Overall agreement and disagreement between c6800 and NMDx results are indicated in bold.

---

**Fig. 1.** Ct-values determined with the SARS-CoV-2 assays for the c6800 and the NMDx system separated to the target gene and the respiratory specimen. The c6800 SARS-CoV-2 assay detects the nonstructural ORF1 gene and the structural E gene. The NMDx SARS-CoV-2 assay detects the nonstructural Nsp2 gene and the structural N gene. The number of PCR cycles is limited to 40 in both assays. Undetected samples are set to a Ct-value of 41. Median Ct-value and IQR (25% – 75%) are indicated in bars. NPS: nasopharyngeal swab.
automation of laboratory-developed real-time RT-PCR test (LDT) for SARS-CoV-2 as early as autumn 2020 [1]. Commercial reagents for SARS-CoV-2 for the c6800 and the NMDx platform became available in summer 2020. Both platforms use a dual-target system and achieve full automation and thus higher sample throughput. Both assays showed convincing analytical and clinical performance compared to other commercial assays [24,25].

Comparative testing of 180 respiratory specimens from 36 different SARS-CoV-2-positive study participants using both platforms revealed no significant differences in detection rates between the c6800 and NMDx SARS-CoV-2 assays when using recommended specimens such as nasopharyngeal swabs, anterior nasal swabs, or throat swabs. The c6800 assay has been shown in previous comparative analyses to be effective in qualitative detection of SARS using nasopharyngeal swabs [26] as well as various other clinical samples such as sputum, bronchial aspirate, bronchoalveolar lavage and anal swabs [25]. In contrast we saw substantially lower detection rates in our study using saliva swabs and gargle lavages.

While anterior nasal and pharyngeal swabs were only slightly less sensitive than the NPS, as previously observed in other studies [27,28], both the saliva swab and gargle lavage showed 20% lower detection rates on average compared to the NPS. This is particularly evident when looking at the agreement of SARS-CoV-2 detection between the two assays. The concordances for saliva swabs and gargle lavage were <90% compared to the other materials with 100% concordances. Here, the discordance could primarily be attributed to the nondetection with the NMDx assay. However, it should be considered that the discrepancies between the assays were only observed in samples with low viral loads, i.e., Ct-values >32. An inferior analytical sensitivity in the low-viremic range is expected, however, the sensitivity may differs between different assays [29].

To address whether the discordant results between the two compared assays were due to differences in the sensitivity of individual target genes used in the assays, we compared not only the Ct-values of the different materials but also the Ct-values of the individual targets. We observed minor differences in analytical sensitivity between the different targets, which were primarily differences between the genes coding for structural and nonstructural proteins and not between the selected target genes of the assays. At lower viral loads (high Ct-values), which we detected with saliva swabs and gargle lavages, the number of undetected targets increased. Together, no individual target predominantly failed in saliva swabs or gargle lavages suggesting that detection of all targets were similarly affected in these specimens.

Although other studies have shown that both saliva and gargle lavage are suitable alternative respiratory materials for the detection of SARS-CoV-2 [30,31], as already mentioned above, these two materials were clearly inferior in our study. This was most likely due to the fact that we directly, in contrast to the other studies, compared our detection rates to the gold standard, the NPS, which still provides the most sensitive detection for SARS-CoV-2 [32,33], and in addition to the timing of sample collection during the course of infection. As shown by Jamal et al. and Savela and colleagues, saliva specimen present high viral loads only at the onset of infection as differences in sensitivity were greatest for sample pairs collected later in illness [34,35]. Notably, for screening of early infections, saliva may still be an excellent respiratory material, however, in hospitalized and symptomatic patients at a later stage of COVID-19 infection, SARS-CoV-2 RNA concentrations in the upper respiratory tract are typically low or even already undetectable, which needs to be considered for decision making in the hospital.

Table 3
Comparison of the determined SARS-CoV-2 RNA concentrations between various respiratory specimens analyzed with the c6800 and the NMDx assays.

| Specimen          | c6800 (log10 copies/mL, median) (ΔNPS) | NMDx (log10 copies/mL, median) (ΔNPS) |
|-------------------|---------------------------------------|---------------------------------------|
| NPS               | 6.379 (-1.318)                        | 6.415 (-1.777)                        |
| Nasal swab        | 5.061 (-0.794)                        | 4.802 (-0.904)                        |
| Throat swab       | 5.585 (-0.794)                        | 5.476 (-0.804)                        |
| Saliva swab       | 3.932 (-2.447)                        | 3.792 (-2.587)                        |
| Gargle lavage     | 4.114 (-2.264)                        | 3.527 (-2.852)                        |

NPS = nasopharyngeal swab.
The SARS-CoV-2 RNA concentration plays an important role for the patient management in terms of isolation measures and treatment decisions. Quantitative analysis of SARS-CoV-2 RNA is therefore common practice. Overall, similar SARS-CoV-2 RNA levels were detected with both platforms depending on the respiratory specimen. As shown in other studies [35,36], the NPS showed the highest SARS-CoV-2 RNA concentrations in the quantitative comparisons between the different specimen, followed by nasal and throat swab with an average of 1 log level lower SARS-CoV-2 RNA concentrations according to the determined Ct-values. Thus, as expected, both saliva swab and gargle lavage were inferior in this quantitative evaluation in our comparative study.

Taken together, both SARS-CoV-2 assays showed comparable results in both, detection and quantification of SARS-CoV-2 RNA. Differences were only found between the different respiratory specimens analyzed. Possible reasons for reduced sensitivity of saliva swabs and gargle lavages are less viral shedding in this compartment, lower stability of the SARS-CoV-2 RNA, and/or a higher dilution factor for the SARS-CoV-2 RNA, related to the specimen heterogeneity [37,38].

It should be noted that only samples from 36 study participants were examined, which represents a relatively small study cohort and represents a limitation of our study. A comparative analysis with a larger cohort could possibly disentangle the reasons for discordant results in the low viremic samples in more detail. Importantly, both SARS-CoV-2 assays utilized in this study were validated and CE-marked for nasal, nasopharyngeal and pharyngeal swabs only. In light of our results these specimens indeed showed higher SARS-CoV-2 RNA concentrations compared to less invasive materials and should be considered as the gold standard for COVID-19 diagnostics. Nevertheless, there may be a role for SARS-CoV-2 quantification from minimally invasive materials in certain patient groups, if it is ensured that the same specimens are longitudinally compared.

5. Conclusions

This study shows that both the c6800 and the NMDx SARS-CoV-2 assays are highly reliable with the recommended specimens and generate valid results. When a quantitative reference material was used as a standard, no relevant differences could be observed in the quantification of the respiratory materials between the assays, while saliva swabs and gargle lavages were clearly inferior in our study cohort. Importantly, these data indicate that not all respiratory specimens are equally suitable for the management of hospitalized patients, especially when dealing with the late phase of COVID-19 in hospitalized patients, where viral replication is declining and inflammation becomes the predominant factor, which makes both, the detection of lower levels of virus but also the quantitative longitudinal courses of SARS-CoV-2-RNA increasingly important.

Acknowledgment

We would like to thank all study participants and medical personnel who made it possible to obtain the respiratory study samples.

Funding

This work was supported by the Ministry for Work, Health and Social Affairs of the State of North Rhine-Westphalia (CPS-1–1A).

Declaration of competing interests

All authors declare no competing interests.

Author statement

Manuscript title: Quantitative analysis of different respiratory specimens on two automated test systems for detection of SARS-CoV-2 RNA

All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication before its appearance in the Diagnostic Microbiology & Infectious Disease.

Author contributions

Nadine Lübke: project administration, conceptualization, investigation, data curation, validation, writing original draft. Katharina Repges: investigation, data curation, review and editing of draft. Christopher Menne: formal analysis, validation, review and editing of draft. Andreas Walker: validation, review and editing of draft. Björn Jensen: conceptualization, resources, review and editing of draft. Noemi F. Freise: resources, review and editing of draft. Smaranda Gliga: resources, review and editing of draft. Simon Eckhoff: formal analysis, review and editing of draft. Hans Martin Bosse: conceptualization, resources, review and editing of draft. Ortwin Adams: formal analysis, review and editing of draft. Jörg Timm: supervision, conceptualization, validation, review and editing of draft.

Supplementary materials

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.diagmicrobio.2022.115800.

References

[1] Corman VM, Landt O, Kaiser M, Molkenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-ncov) by real-time RT-PCR. Euro Surveill 2020;25(3):200045.
[2] Barra GB, Santa Rita TH, Mesquita NG, Jacomo BH, Nery LFA. Overcoming supply shortage for SARS-CoV-2 Detection by RT-qPCR. Genes (Basel) 2021;12(1):90.
[3] Lübke N, Senff T, Schérer S, Hauka S, Andree M, Adams O, et al. Extraction-free SARS-CoV-2 detection by rapid RT-qPCR universal for all primary respiratory materials. J Clin Virol 2020;130:104579.
[4] WHO. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). World Health Organisation; 2020 Available from: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-reportpdf. Accessed October 11, 2022.
[5] Bennett S, Davidson RS, Gunson RN. Comparison of gargle samples and throat swab samples for the detection of respiratory pathogens. J Virol Methods 2017;248:83–6.
[6] Roche. Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark. Roche; 2020 Available from: https://www.roche.com/media/releases/med-cor-2020-03-11.htm. Accessed October 11, 2022.
[7] FDA. Vitro diagnostics EUAs – molecular diagnostic tests for SARS-CoV-2. 2021.
[8] Rhoads DD, Cherian SS, Roman K, Stempak LM, Schmotzer CL, Sadri N. Comparison of Abbott ID now, DiaSorin Simplexa, and CDC FDA emergency use authorization methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19. J Clin Microbiol 2020;58(8):e00760–20.
[9] Hoenh S, Kreutzer E, Schenck B, Westhaus S, Foppa I, Herrmann E, et al. Longitudinal testing for respiratory and gastrointestinal shedding of SARS-CoV-2 in day care centres in Hesse, Germany. Clin Infect Dis 2021;73(9):e3036–41.
[10] Joachim A, Dewald F, Suarez I, Zemlin M, Lang I, Stutz R, et al. Pooled RT-qPCR testing for SARS-CoV-2 surveillance in schools - a cluster randomised trial. E Clinical Medicine 2021;39:101082.
[11] Lübke N, Schupp A-K, Bredahl R, Kraus U, Hauka S, Andree M, et al. Screening for SARS-CoV-2 infections in daycare facilities for children in a large city in Germany. medRxiv 2021.02.26;2021:21252150.
[12] CDC. COVID-19 Vaccines for Children and Teens. 2021.
[13] Cui X, Zhao Z, Zhang T, Guo W, Guo W, Zheng J, et al. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). J Med Virol 2021;93(2):1057–69.
Li M, Wei R, Yang Y, He T, Shen Y, Qi T, et al. Comparing SARS-CoV-2 testing in
Kheiroddin P, Sch.
Ibrahimi N, Delaunay-Moisan A, Hill C, Le Teuff G, Rupprecht JF, Thuret JY, et al. Evalu-
Alqahtani M, Abdulrahman A, Mustafa F, Alawadhi AI, Alalawi B, Mallah SI. Evalu-
SARS-COV-2 DIAGNOSTIC PIPELINE. 2022 Available from: https://www.instand-ev.de/
INSTAND. Quantitative Bezugsproben zur Verbesserung der Vergleichbarkeit und
Saito M, Adachi E, Yamayoshi S, Koga M, Iwatsuki-Horimoto K, Kawaoka Y, et al.
Goldfarb DM, Tilley P, Al-Rawahi GN, Srigley JA, Ford G, Pedersen H, et al. Self-col-
lected saline gargle samples as an alternative to health care worker-collected
nasopharyngeal swabs for COVID-19 diagnosis in outpatients. J Clin Microbiol
2021;59(4):e02427–20.
Safto M, Adachi E, Yamayoshi S, Koga M, Iwatsuki-Horimoto K, Kawarka Y, et al.
Gargle Lavage as a Safe and Sensitive Alternative to Swab Samples to Diagnose
COVID-19: A Case Report in Japan. Clinical Infectious Diseases: an official publica-
tion of the Infectious Diseases Society of America 2020;71(15):893–4.
INSTAD. Quantitative Bezugsproben zur Verbesserung der Vergleichbarkeit und
Bewertung von Laborergebnissen zum Virusgenom-Nachweis von SARS-CoV-2. 2021
Available from: https://www.instand-ev.de/fileadmin/uploads/user_upload/Dokumente/Virologie/20210118_Begleitheft_-_quantitative_Bezugsprobe-
n_1_und_2_-_SARS-CoV-2.pdf. Accessed October 11, 2022.
SARS-CoV-2 DIAGNOSTIC PIPELINE. 2022 Available from: https://www.fnddx.
org/covid-19/pipeline/. Accessed October 11, 2022.
List of SARS-CoV-2 Diagnostic test kits and equipments eligible for procurement
according to Board Decision on Additional Support for Country Responses to
COVID-19 (GF/B42/EDP11). 2022 Available from: https://www.theglobalfund.org/
media/9629/covid19_diagnosticproducts_list_en.pdf. Accessed January 17, 2022.
Alqahtani M, Abdulrahman A, Mustafa F, Alawadhi AI, Alalawi B, Mallah SI. Evalua-
tion of rapid antigen tests using nasal samples to diagnose SARS-CoV-2 in sympt-
omat ic patients. Front Public Health 2021;9:728069.
Ibrahim N, Delanauy-Moisan A, Hill C, Le Teuff G, Rupprecht JF, Thuret JY, et al.
Screening for SARS-CoV-2 by RT-PCR: Saliva or nasopharyngeal swab? Rapid
review and meta-analysis. PLoS One 2021;16(6):e0253907.
Khreidddin P, Schobert P, Althammer M, Cibali E, Wurfel T, Wein H, et al. Results
of WICOVIR gargle pool PCR testing in german schools based on the first 100,000
tests. Front Pediatr 2021;9:721518.
Li M, Wei R, Yang Y, He T, Shen Y, Qi T, et al. Comparing SARS-CoV-2 testing in
anterior nasal vestibular swabs vs. oropharyngeal swabs. Front Cell Infect Micro-
biol 2021;11:653794.
Li M, Wei R, Yang Y, He T, Shen Y, Qi T, et al. Comparing SARS-CoV-2 testing in
anterior nasal vestibular swabs vs. oropharyngeal swabs. Front Cell Infect Micro-
biol 2021;11:653794.
Mustafa HH, Lamson DM, Ulhteg K, Goaehr M, Gluck L, de Cardenas JNB, et al. Multi-
center evaluation of the NeuMoDx SARS-CoV-2 Test. J Clin Virol 2020;130:104583.
Opota O, Brouillet R, Greub G, Jaton K. Comparison of SARS-CoV-2 RT-PCR on a
high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for
the diagnosis of COVID-19 on various clinical samples. Pathog Dis 2020;78 (8):ftaa061.